EUR/USD
1.14513
0.169%
Gold
4175.00
1.245%
Oil
69.136
1.049%
USD/JPY
161.141
0.023%
GBP/USD
1.33692
0.175%
GBP/JPY
215.438
0.213%
Real-time News
On July 3, European Central Bank President Christine Lagarde hinted on July 2 that she did not rule out the possibility of resigning her current post and running in next years French presidential election. In an interview that day, when asked if she would consider leaving office early if the eurozone inflation situation stabilized, Lagarde replied, "Possibly. I think there should be a European voice in the French presidential election." She also commented on Frances relationship with the EU, stating that if a presidential candidate raises the idea of "reducing Frances involvement in the EU" during election debates, someone needs to explain to voters that this path is not easy. "France will have to make bold decisions on thorny issues," she said, adding that voters expect to be told the truth and offered solutions, and "presidential candidates have a responsibility to examine these issues and propose solutions." When asked whether she would support a candidate or run herself, Lagarde initially answered "Im considering it," but then quickly corrected herself, saying she was joking.Indias final composite PMI for June was 57.1, compared to 57.4 in the previous month.On July 3rd, Faraday Future (FFIE.O) issued a statement clarifying that it has noticed false information circulating on some online platforms claiming that FFs Los Angeles headquarters is deserted. The statement clarified that FFs Hanford factory has not closed, and the relocation of its global headquarters to El Segundo, Los Angeles, is a normal process. The location of the video circulating online is FFs former headquarters in Gardena, which ceased to be used by FF at the end of March this year.The China Earthquake Networks Center officially determined that a magnitude 3.0 earthquake occurred at 12:44 on July 3 in Haixi Prefecture, Qinghai Province (37.86 degrees north latitude, 95.40 degrees east longitude), with a focal depth of 10 kilometers.On July 3rd, UBS released a research report stating that it recently invited Innovent Biologics (01801.HK) to participate in its virtual healthcare roadshow. Following strong product sales in the first quarter, management stated that sales momentum remained solid in the second quarter, viewing it as the new normal rather than a new shock, primarily supported by high unmet demand in its innovative product portfolio. Regarding GLP-1 drugs, management did not feel pressured by tightening online channels, noting that the recent 618 e-commerce event showed healthy demand across the category. UBS has included Pfizers licensing revenue and abexilic acid sales in its forecasts. However, considering the R&D commitments of the collaborative assets, it increased its R&D expense forecasts for 2026-2028, resulting in a downward revision of its 2026-2028 EPS forecasts from RMB 1.13, RMB 2.91, and RMB 4.41 to RMB 1.12, RMB 2.41, and RMB 3.42, respectively. UBS slightly raised its target price for Innovent Biologics from HKD 124 to HKD 124.1, reiterating its buy rating.
